We offer standardized cellular models covering a broad range of tumor-associated antigens (TAAs), including key targets such as 5T4, B7H3, CD123, CD19, CD20, CD22, CD30, CD33, and CD38. This platform supports in vitro activity evaluation and screening for antibody drugs, CAR-T therapies, and bispecific antibodies, providing efficient and reliable detection tools for cancer immunotherapy development.
